MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$18,692K
Net Income
-$6,373K
Net Profit Margin
-34.09%
EPS
-$0.33
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
18,692
12,648
13,686
19,066
Research and development
14,559
19,832
18,122
14,321
General and administrative
7,624
6,928
7,400
6,674
Total operating expenses
22,183
26,760
25,522
20,995
Loss from operations
-3,491
-14,112
-11,836
-1,929
Change in fair value of common stock warrant liabilities
3,940
-3,300
-21,275
15,380
Other income (expense), net
1,058
1,283
921
1,022
Total other income (expense), net
-2,882
4,583
22,196
-14,358
Net gain and comprehensive gain
-6,373
-9,529
10,360
-16,287
Basic EPS
-0.33
-0.58
1.239
-0.11
Diluted EPS
-0.33
-0.58
-1.048*
-0.11
Basic Average Shares
19,404,688
16,347,538
8,359,109*
144,106,869
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net gain and
comprehensive gain
-$6,373K
(59.78%↑ Y/Y)
Loss from operations
-$3,491K
(75.70%↑ Y/Y)
Total other income
(expense), net
-$2,882K
(-94.99%↓ Y/Y)
Total revenue
$18,692K
(131.22%↑ Y/Y)
Other income
(expense), net
$1,058K
(174.09%↑ Y/Y)
Total operating
expenses
$22,183K
(-1.19%↓ Y/Y)
Change in fair value of
common stock warrant...
$3,940K
(7780.00%↑ Y/Y)
Research and development
$14,559K
(-5.03%↓ Y/Y)
General and
administrative
$7,624K
(7.08%↑ Y/Y)
Buy us a coffee
Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc. (XLO)